200 related articles for article (PubMed ID: 36729276)
1. Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study.
Lycke J; Farman H; Nordin A
CNS Drugs; 2023 Feb; 37(2):181-188. PubMed ID: 36729276
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
5. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
8. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
[TBL] [Abstract][Full Text] [Related]
10. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
11. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
13. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide and its mechanism of action in multiple sclerosis.
Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
[TBL] [Abstract][Full Text] [Related]
17. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Miller AE
Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
[TBL] [Abstract][Full Text] [Related]
18. From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Aly L; Hemmer B; Korn T
Curr Neuropharmacol; 2017; 15(6):874-891. PubMed ID: 27928949
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
